@article{ea3a067736f04cdeb1bd0c5b24f6f697,
title = "Priority covid-19 vaccination for patients with cancer while vaccine supply is limited",
abstract = "Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.",
author = "Antoni Ribas and Rajarshi Sengupta and Trevan Locke and Zaidi, {Sayyed Kaleem} and Campbell, {Katie M.} and Carethers, {John M.} and Jaffee, {Elizabeth M.} and {John Wherry}, E. and Soria, {Jean Charles} and Gypsyamber D{\textquoteright}souza",
note = "Funding Information: A. Ribas reports personal fees from Amgen (honoraria), Chugai (honoraria), Genentech (honoraria), Merck (honoraria), Novartis (honoraria), Roche (honoraria), Sanofi (honoraria), Vedanta (honoraria), Advaxis (scientific advisory board member, honoraria, stock), Apricity (scientific advisory board member, honoraria, stock), Arcus (scientific advisory board member, honoraria, stock), Compugen (scientific advisory board member, honoraria, stock), CytomX (scientific advisory board member, honoraria, stock), Five Prime (scientific advisory board member, honoraria, stock), Highlight (scientific advisory board member, honoraria, stock), ImaginAb (scientific advisory board member, honoraria, stock), Isoplexis (scientific advisory board member, honoraria, stock), Kite/Gilead (scientific advisory board member, honoraria, stock), Lutris (scientific advisory board member, honoraria, stock), Merus (scientific advisory board member, honoraria, stock), PACT (scientific advisory board member, honoraria, stock), RAPT (scientific advisory board member, honoraria, stock), Rgenix (scientific advisory board member, honoraria, stock), and Tango Therapeutics (scientific advisory board member, honoraria, stock) and grants from NCI, Agilent, Bristol-Myers Squibb through Stand Up To Cancer (SU2C), the Melanoma Research Alliance, and the Parker Institute for Cancer Immunotherapy outside the submitted work. R. Sengupta, T. Locke, and S.K. Zaidi are employed by the American Association for Cancer Research. E.M. Jaffee reports grants from Bristol-Myers Squibb; personal fees from Genocea (consultation), Achilles (consultation), DragonFly (consultation), and CSTONE (consultation); other from AbMeta (founder) and PICI (consultant); and reports grants from and is the Chief Medical Advisor for Lustgarten Foundation outside the submitted work. No disclosures were reported by the other authors. Publisher Copyright: {\textcopyright} 2020 American Association for Cancer Research.",
year = "2021",
month = feb,
doi = "10.1158/2159-8290.CD-20-1817",
language = "English (US)",
volume = "11",
pages = "233--236",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "2",
}